Abstract
Drug-induced diabetes insipidus is always of the nephrogenic type, i.e. unre-sponsiveness of the kidneys to the action of antidiuretic hormone. This condition is easily diagnosed by measuring urinary concentrating capacity during a thirst test (e.g. 12 hours of water deprivation) or by administration of a modified anti-diuretic hormone, desmopressin, to demonstrate the renal unresponsiveness. Drug-induced nephrogenic diabetes insipidus is not a common disorder except in patients receiving treatment with lithium salts for affective disorders where it may affect about 10% of patients treated long term (15 years). Drug-induced nephrogenic diabetes insipidus caused by other drugs usually occurs in critically ill patients in intensive care units receiving a multitude of drugs dominated by antimicrobials and cytostatics. A search of the World Health Organization’s adverse effect database revealed 359 reports of drug-induced diabetes insipidus. Lithium was the most common cause (159 reports) followed by foscarnet (15) and clozapine (10).
Treatment is symptomatic in most patients and the offending drug should be stopped. If urine volumes exceed 4 L/day, treatment with thiazides and amiloride has been advocated, and nonsteroidal anti-inflammatory drugs, such as indometh-acin, may be tried in severe cases. Prevention of lithium-induced nephrogenic diabetes insipidus is an important aspect of the treatment of affective disorders.
In patients treated long term it appears to be only partly reversible upon lithium discontinuation. Close monitoring of the treatment aiming at 12-hour trough value of 0.4 to 0.6 mmol/L is recommended. Yearly measurement of the urinary volume/day is effective in making both the patient and the physician aware of the development of the drug-induced nephrogenic diabetes insipidus. The condition is a serious adverse effect because of the risk of developing dehydration and aggravation of drug intoxications.
Similar content being viewed by others
References
Reeves WB, Bichet DG, Andreoli TE, et al. Posterior pituitary and water metabolism. In: Wilson JD, Foster DW, Kronenberg HM, et al., editors. Williams textbook of Endocrinology. 9th ed. Philadelphia (PA); Saunders, 5: 341–87
Blevins Jr LS, Wand GS. Diabetes insipidus. Crit Care Med 1992; 20: 69–79
Seckl JA, Dunger DB. Diabetes insipidus — current treatment recommendations. Pract Ther Drugs 1992; 44: 216–24
Knepper MA, Verbalis JG, Nielsen S. Role of aquaporins in water balance disorders. Curr Opin Nephrol Hypertens 1997; 6: 367–71
Nielsen S, Marples D, Frøkiæsr J, et al. The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Kidney Int 1996; 49: 1718–23
Navarro JF, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996; 27: 431–4
Farese Jr RV, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 1990; 112: 955–6
Coon J, Colman P, Brown G, et al. Nephrogenic diabetes insipidus associated with foscarnet — a case report. J Antimicrob Chemother 1996; 37: 1179–81
Force G, Blanchard A, Leviel F, et al. Nephrogenic diabetes insipidus related to foscarnet and thirst loss related to CMV encephalitis in AIDS patient [abstract]. 11th International Conference on AIDS: 1996 Jul 7–12; Vancouver, 87
Jarousse B, Launay O, Lortholary O, et al. Nephrogenic diabetes insipidus induced by foscarnet treatment of cytomegal-virus retinitis. 7th European Congress of Clinical Microbiology and Infectious Diseases; 1995 Mar 26–30; Vienna, 165
Schliefer K, Rockstroh JK, Spengler U. Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 1997; 350: 413–4
Smith OP, Gale R, Hamon M, et al. Amphotericin B-induced nephrogenic diabetes insipidus: resolution with its liposomal counterpart. Bone Marrow Transplant 1994; 13: 107–8
Hauohler T, Teuber G, Wanitschke R, et al. Indomethacin treatment in amphotericin B induced nephrogenic diabetes insipidus. Clin Investig 1994; 72: 769–71
Benazzi F, Mazzoli M. Polydipsia induced by fluvoxamine [letter]. Pharmacopsychiatry 1993; 26: 63
Mallet H, Dupond JL. Vascularitis and diabetes insipidus, reversible by administration of cyclophosphamide [letter]. Presse Med 1995; 24: 1709
Mullen PJ. Polyuria and weight-loss associated with cimetidine [letter]. Postgrad Med J 1992; 68: 771
Sakane N, Yoshida T, Umekawa T, et al. Nephrogenic diabetes insipidus induced by lobenzarit disodium treatment in patients with rheumatoid arthritis. Intern Med 1996; 35: 119–22
Nishinarita S, Hayakawa J, Suzuki R, et al. Lobenzarit disodium (CCA)-induced diabetes insipidus in a patient with rheumatoid arthritis. Ryumachi 1992; 32: 333–7
Vasey PA, Dunlop DJ, Steward WP. Nephrogenic diabetes insipidus following high dose epirubicin chemotherapy for met-astatic soft tissue carcinoma [letter]. Eur J Cancer 1995; 31A (Pt A): 126
Glusac E, Patel H, Josef NC, et al. Polydipsia and hyponatremia induced by multiple neuroleptics but not molindone. Can J Psychiatry 1990; 35: 268–9
Fioriti A. Heavy cigarette smoking and polydipsia induced by neuroleptic medication [letter]? Eur Psychiatry 1997; 12: 156
Schwartz ID, Scagliotti D. Verapamil-induced primary polydipsia. Pediatr Cardiol 1995; 16: 228–30
Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349–52
Baastrup PC, Schou M. Lithium as a prophylactic agent. Its effect against recurrent depression and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162–72
Baastrup PC, Poulsen JC, Schou M, et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; II: 326–30
Coppen A, Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders. Lancet 1971; II: 275–9
Noack CH, Trautner EM. The lithium treatment of maniacal psychosis. Med J Aust 1951; 2: 219–22
Schou M. Lithium in psychiatric therapy. Stock-taking after ten years. Psychopharmacologia 1959; 1: 65–78
Angrist BM, Gershon S, Levitan SJ, et al. Lithium induced diabetes insipidus-like syndrome. Compr Psychiatry 1970; 11: 141–6
Lee RV, Jampol LM, Brown WV. Nephrogenic diabetes insipidus and lithium intoxication — complications of lithium carbonate therapy. N Engl J Med 1971; 284: 93–4
Forrest JN, Cohen AD, Torretti J, et al. On the mechanism of lithium induced diabetes insipidus in man and in the rat. J Clin Invest 1974; 53: 1115–23
Evan AP, Ollerich DA. The effect of lithium carbonate on the structure of the rat kidney. Am J Anat 1972; 134: 97–106
Lindop GBM, Padfield PL. The renal pathology in a case of lithium induced diabetes insipidus. J Clin Pathol 1975; 28: 472–5
Hestbech J, Hansen HE, Amdisen A, et al. Chronic renal lesions following long-term treatment with lithium. Kidney Int 1977; 12: 205–13
Hansen HE. Renal toxicity of lithium. Drugs 1981; 22: 461–76
Aurell M, Svalander C, Wallin L, et al. Renal function and biopsy findings in patients on long-term lithium treatment. Kidney Int 1981; 20: 663–70
von Knorring L, Wahlin A, Nyström K, et al. Uraemia induced by long-term lithium treatment. Lithium 1990; 1: 251–3
Hayslett JP, Kashgarian M. A micropuncture study of the renal handling of lithium. Pflugers Arch 1979; 380: 159–63
Marples D, Christensen S, IlsøChristensen E, et al. Lithium induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 1995; 95: 1838–45
Batlle DC, von Riotte AB, Gaviria M, et al. Amelioration of Polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985; 312: 408–14
Christensen S. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of lithium-induced polyuria in the rat. Scand J Clin Lab Invest 1980; 40: 151–7
Bendz H, Sjödin I, Toss G, et al. Hyperparathyroidism and long-term lithium therapy — a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996; 240: 357–65
Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10: 329–45
Bendz H, Aurell M, Balldin J, et al. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant 1994; 9: 1250–4
Gray EJ, Dierks EJ. Lithium-induced diabetes insipidus in a surgical patient: report of a case and review of the literature. J Oral Maxillofac Surg 1996; 54: 909–12
Vestergaard P, Thomsen K. Renal side effects of lithium: the importance of the serum lithium level. Psychopharmacology 1981; 72: 203–4
Post RM, Ketter TA, Denicoff K, et al. The place of anticonvul-sant therapy in bipolar illness. Psychopharmacology 1996; 128: 115–29
Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium versus carbamazepin in the maintenance treatment of bipolar disorders — a randomised study. J Affect Disord 1997; 43: 151–61
Greil W, Ludwig-Mayerhofer W, Erazo N, et al. Lithium vs carbamazepin in the maintenance treatment of schizoaffective disorder: a randomised study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 42–50
Lambert PA, Venaud G. Étude comparative du valpromide versus dans la prophylaxie des troubles thymiques. Nervure 1992; 5(2): 57–65
Höhler T, Teuber G, Wanitschke R, et al. Indomethacin treatment in amphotericin B induced nephrogenic diabetes insipidus. Clin Investig 1994; 72: 769–71
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bendz, H., Aurell, M. Drug-Induced Diabetes Insipidus. Drug-Safety 21, 449–456 (1999). https://doi.org/10.2165/00002018-199921060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199921060-00002